Literature DB >> 9085184

Strategy for designing specific antisense oligonucleotide sequences.

M Mitsuhashi1.   

Abstract

Antisense compounds, various forms of nucleotides or their analogs, inhibit gene function both in vitro and in vivo. Although antisense compounds have been used extensively not only as a basic research tool but also as therapeutics for various diseases, one of the major problems is the difficulty of obtaining optimal sequences to inhibit specific gene functions. Although the terms "sequence-specificity" or "sequence-nonspecificity" are often used, there is no consensus as to how to define and quantitate such sequence specificity. In this review, we introduced hybridization simulation for designing optimal antisense sequences. Each candidate antisense oligonucleotide is assessed by calculating its hybridization energy against potential hybridization sites within the specified database (including GenBank) using a realistic nearest-neighbor thermodynamic model, taking into account mismatches. The specificity of each oligonucleotide is then quantitated by the number of potential cross-hybridizable genes and their degree of cross-hybridization. Furthermore, if antisense sequences exhibit a high potential for hairpin formation, they are not recommended even if they are highly specific. Therefore, to select antisense sequences, one should calculate all the potential factors for each candidate oligonucleotide such as length, location, specificity, hairpin potential, mRNA secondary structure, and dimer formation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9085184     DOI: 10.1007/bf02936384

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  34 in total

Review 1.  RNA structure prediction.

Authors:  D H Turner; N Sugimoto; S M Freier
Journal:  Annu Rev Biophys Biophys Chem       Date:  1988

2.  Improved tools for biological sequence comparison.

Authors:  W R Pearson; D J Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

3.  Predicting DNA duplex stability from the base sequence.

Authors:  K J Breslauer; R Frank; H Blöcker; L A Marky
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

4.  Short antisense oligonucleotide-mediated inhibition is strongly dependent on oligo length and concentration but almost independent of location of the target sequence.

Authors:  B Fakler; S Herlitze; B Amthor; H P Zenner; J P Ruppersberg
Journal:  J Biol Chem       Date:  1994-06-10       Impact factor: 5.157

5.  Oligonucleotide probe design--a new approach.

Authors:  M Mitsuhashi; A Cooper; M Ogura; T Shinagawa; K Yano; T Hosokawa
Journal:  Nature       Date:  1994-02-24       Impact factor: 49.962

6.  Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages.

Authors:  E P Stirchak; J E Summerton; D D Weller
Journal:  Nucleic Acids Res       Date:  1989-08-11       Impact factor: 16.971

7.  Antisense oligodeoxyribonucleotide inhibition of TGF-beta 1 gene expression and alterations in the growth and malignant properties of mouse fibrosarcoma cells.

Authors:  M Spearman; W R Taylor; A H Greenberg; J A Wright
Journal:  Gene       Date:  1994-11-04       Impact factor: 3.688

8.  Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects.

Authors:  R Zhang; J Yan; H K Shahinian; H Shahinian; G Amin; Z Lu; T Liu; M S Saag; Z Jiang; J Temsamani; R R Martin
Journal:  Clin Pharmacol Ther       Date:  1995-07       Impact factor: 6.875

9.  Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37.

Authors:  G S Pari; A K Field; J A Smith
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

10.  Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice.

Authors:  R M Burch; L C Mahan
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.